A-dmDT390-bisFv (UCHT1)

N/A

Report date: 2026/05/20 20:02:01

Base Information

Drug NameA-dmDT390-bisFv (UCHT1)
Drug Alias NameUCHT-1-AngimmuneA-dmDT390-anti-CD3 immunotoxinRecombinant anti-CDR-bi-single-chain-Fv-diptheria toxin fusion proteinResimmuneLAX-699
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-chain FV antibody fragment (scFv)Biologics > Protein drugs > Toxin
Mechanisms of ActionAnti-CD3Protein biosynthesis inhibitors
TargetsT cell surface glycoprotein CD3
Therapy Area/IndicationsMelanomaSezary SyndromeMycosis Fungoides +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNational Institutes Of Health
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesVirogen Biotechnology IncAngimmune Llc
Active IndicationsN/A
Inactive IndicationsMelanomaSezary SyndromeMycosis Fungoides +[6] 

Other Information

ATC CodeN/A
Related LinksWikipedia